The potential impact of chronic obstructive pulmonary disease in lung cancer screening: implications for the screening clinic

References

• Shlomi D, Ben-Avi R, Balmor RG, et al. Screening for lung cancer: time for large-scale screening by chest computed tomography. Eur Respir J. 2014;44:217–238.
   PubMed Web of Science ®Google Scholar
• Young RP, Hopkins RJ. Chronic obstructive pulmonary disease (COPD) and lung cancer screening. Transl Lung Cancer Res. 2018;7(3):347–360.
   PubMed Web of Science ®Google Scholar
• National Lung Screening Trial Research team, Aberle DR, Adams AM, Berg CD, et al. Reduced lung cancer mortality with low dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.
   PubMed Web of Science ®Google Scholar
• De Koning H, Van Der Aalst C, Ten Haaf K, et al. Effects of volume CT lung cancer screening: mortality results of the NELSON randomised-controlled population based trial. Presented at: IASLC 19th World Conference on Lung Cancer; Toronto, Canada; September 23–26, 2018. Abstract PL02.05.
   Google Scholar
• Chung M, Tam K, Wallace C, et al. International early lung cancer action program: update on lung cancer screening and the management of CT screen-detected findings. AME Med J. 2017;2(129):1–15.
   Google Scholar
• Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in the National lung screening trial. N Engl J Med. 2014;371:1793–1802.
   PubMed Web of Science ®Google Scholar
• Young RP, Hopkins RJ. Measures of outcome in lung cancer screening: maximising the benefits. J Thorac Dis. 2016;8(10):E1317–E1320.
   PubMed Web of Science ®Google Scholar
• Pinsky PF, Church TR, Izmirlian G, et al. The National lung screening trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer. 2013;119:3976–3983.
   PubMed Web of Science ®Google Scholar
• Young RP, Duan F, Greco E, et al. Lung cancer specific mortality reduction with CT screening: outcomes according to airflow limitation in the ACRIN-NLST study (N=18,475). Am J Respir Crit Care Med. 2016;193:A6166.
   Web of Science ®Google Scholar
• Hopkins RJ, Duan F, Chiles C, et al. Reduced expiratory flow rates among heavy smokers increases lung cancer risk: results from the National lung screening trial-American College of radiology imaging network cohort. Ann ATS. 2017;14:392–402.
   Google Scholar
• Hopkins RJ, Ko J, Gamble GD, et al. Lung cancer surgery for early stage non-small cell lung cancer: systematic review of mortality according to the presence of COPD. Am J Respir Crit Care Med. 2017;195:A4887.
   Web of Science ®Google Scholar
• Hopkins RJ, Young RP, Duan F, et al. Lung cancer screening and the effects of competing causes of death in the ACRIN-NLST. Am J Respir Crit Care Med. 2017;195:A5174.
   Web of Science ®Google Scholar
• Young RP, Duan F, Chiles C, et al. Airflow limitation and histology-shift in the National lung screening trial: the NLST-ACRIN cohort study (N=18,714). Am J Respir Crit Care Med. 2015;192:1060–1067.
   PubMed Web of Science ®Google Scholar
• Patz EF, Pinsky P, Gatsonis C, et al. Overdiagnosis in computed-tomography screening for lung cancer. JAMA Int Med. 2014;174:269–274.
   PubMed Web of Science ®Google Scholar
• Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med. 2008;178:738–744.
   PubMed Web of Science ®Google Scholar
• de Torres JP, Marin JM, Casanova C, et al. Lung cancer in patients with chronic obstructive pulmonary disease – incidence and predicting factors. Am J Respir Crit Care Med. 2001;184:913–919.
   Google Scholar
• Carr LL, Jacobson S, Lynch DA, et al. Features of COPD as predictors of lung cancer. Chest. 2018;153(6):1326–1335.
   PubMed Web of Science ®Google Scholar
• Gierada DS, Guniganti P, Newman BJ, et al. Quantitative CT assessment of emphysema and airways in relation to lung cancer risk. Radiology. 2011;261(3):950–959.
   PubMed Web of Science ®Google Scholar
• Humphrey LL, Deffebach M, Pappas M, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US preventive services task force recommendation. Ann Int Med. 2013;159(6):411–420.
   PubMed Web of Science ®Google Scholar
• Gould MK. Precision screening for lung cancer: risk-based but not always preference-sensitive. Ann Int Med. 2018;169:52–53.
   PubMed Web of Science ®Google Scholar
• Green AK, Bach P. Model-based eligibility for lung cancer screening: where theory meets practice. Ann Intern Med. 2018;168(3):223–224.
   PubMed Web of Science ®Google Scholar
• Bach PB, Gould MK. When the average applies to no one: personalized decision making about potential benefits of lung cancer screening. Ann Int Med. 2012;157(8):571–573.
   PubMed Web of Science ®Google Scholar
• Tammemagi CM, Pinsky PF, Caporaso NE, et al. Lung cancer risk prediction: prostate, lung, colorectal and ovarian cancer screening trial models and validation. J Natl Cancer Inst. 2011;103:1058–1068.
   PubMedGoogle Scholar
• Katki HA, Kovalchik SA, Berg CD, et al. Development and validation of risk models to select ever-smokers for CT lung cancer screening. JAMA. 2016;315(21):2300–2311.
   PubMed Web of Science ®Google Scholar
• Ten Haaf K, Jeon J, Tammemagi MC, et al. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. PLoS Med. 2017;1–24.
   Web of Science ®Google Scholar
• Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung cancer death. N Eng J Med. 2013;369:245–254.
   PubMed Web of Science ®Google Scholar
• Sigel K, Wisnivesky JP. Comorbidity profiles of pateints with lung cancer: A new approach to risk stratification? AnnalsATS. 2017;14(10):1512–1513.
   Google Scholar
• Young RP, Hopkins RJ, Duan F, et al. The relationship between lung cancer risk according to the PLCOM2012 model and prevalence or presence of COPD in the NLST-ACRIN sub-study (N=10,054). Am J Respir Crit Care Med. 2018;197:A4411.
   Web of Science ®Google Scholar
• Young RP, Hopkins RJ. How the genetics of lung cancer may overlap with COPD. Respirology. 2011;16:1047–1055.
   PubMed Web of Science ®Google Scholar
• Durham AL, Adcock IM. The relationship between COPD and lung cancer. Lung Cancer. 2015;90:121–127.
   PubMed Web of Science ®Google Scholar
• Rivera MP, Tanner NT, Silvestri GA, et al. Incorporating coexisting chronic illness into decisions about patient selection for lung cancer screening. An official american thoracic society research statement. Am J Respir Crit Care Med. 2018;198:e3–e13.
   PubMed Web of Science ®Google Scholar
• Hopkins RJ, Duan F, Chiles C, et al. Lung cancer risk (PLCOM2012) and surgical rates for lung cancer in a post-hoc analysis of the National Lung Screening Trial (NLST-ACRIN substudy, N=10,054). Am J Respir Crit Care Med 2019; 199: A4475.
   Google Scholar
• Tanner NT, Dai L. Bade et al. Assessing the generalizability of the National Lung Screening Trial: comparison of patients with stage 1 disease. Am J Respir Crit Care Med. 2017;196:602–608.
   PubMed Web of Science ®Google Scholar
• Gould MK, Munoz-Plaza CE, Hahn EE, et al. Comorbidity profiles and their effect on treatment selection and survival among patients with lung cancer. AnnalsATS. 2017;14(10):1571–1580.
   Google Scholar
• Tammemagi MC, Church TR, Hocking WG, et al. Evaluation of the lung cancer risks at which to screen ever- and never-smokers; screening rules applied to the PLCO and NLST cohorts. Plos Med. 2014;11:e1001764.
   PubMed Web of Science ®Google Scholar
• Kumar V, Cohen JT, van Klaveren D,  et al. Risk-targeting lung cancer screening: A cost-effectiveness analysis. Ann Int Med. 2018;168(3):161–169.
   PubMed Web of Science ®Google Scholar
• Caverly TJ, Cao P, Hayward RA, et al. Identifying patients for whom lung cancer screening is preference-sensitive. Ann Int Med. 2018;169:1–9.
   PubMed Web of Science ®Google Scholar
• Mackenbach JP, Kunst AE, Lautenbach H, et al. Competing causes of death: a death certificate study. J Clin Epidemiol. 1997;50:1069–1077.
   PubMed Web of Science ®Google Scholar
• Berry SD, Ngo L, Samelson EJ, et al. Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc. 2010;58(4):783–787.
   PubMed Web of Science ®Google Scholar
• Bhatt JR, Klotz L. Overtreatment in cancer – is it problem? Exp Opin Pharmacother. 2016;17:1–5.
   PubMed Web of Science ®Google Scholar
• Iaccarino JM, Clark J, Bolton R, et al. A national survey of pulmonologists’ views on low-dose computed tomography screening for lung cancer. Ann Am Thorac Soc. 2015;12:1667–1675.
   PubMed Web of Science ®Google Scholar
• Ording AG, Garne JP, Nystrom PMW, et al. Comorbid diseases interact with breast cancer to affect mortality in the first year after diagnosis – A Danish nationwide matched cohort study. Plos One. 2013;8:e76013.
   PubMed Web of Science ®Google Scholar
• Erichsen R, Horvath-Puho E, Iversen LH, et al. Does comorbidity interact with colorectal cancer to incraese mortality? A nationwide population-based cohort study. BJC. 2013;109:2005–2013.
   PubMedGoogle Scholar
• Lamerato LE, Marcus PM, Jacobsen G, et al. Recruitment in the prostate, long, coloractal, and ovarian (PLCO) Cancer screening trial: the first phase of recruitment at the Henry Ford health system. Cancer Epidemiol Biomarkers Prev. 2008;17:827–833.
   PubMed Web of Science ®Google Scholar
• Hopkins RJ, Duan F, Chiles C, et al. Lung cancer risk (PLCOM2012) and pre-existing respiratory morbidity in a post-hoc analysis of the national lung screening trial (NLST-ACRIN, N=10054). Am J Respir Crit Care Med 2019; 199: A4476.
   Google Scholar
• Young RP, Duan F, Greco E, et al. Stratification of NLST-ACRIN screening participants identifies the “sweet spot” of screening by identifying early stage lung cancers most amenable to curative surgery (N=10,054). Am J Respir Crit Care Med. 2017;195:A12653.
   Web of Science ®Google Scholar
• Prasad V, Lenzer J, Newman DH. Why cancer screening has never been shown to “save lives” – and what we can do about it. BMJ. 2016;352:h6080.
   PubMed Web of Science ®Google Scholar
• Jemal A, Fedewa SA. Lung cancer screening with low-dose computed tomography in the United States – 2010 to 2015. JAMA Oncol. 2017;3(9):1278–1281.
   PubMed Web of Science ®Google Scholar
• Modin HE, Fathi JT, Gilbert CR, et al. Pack-year cigarette smoking history for determination of lung cancer screening eligibility. Comparison of the electroinc medical record versus a shared decision-making conversation. AnnalsATS. 2017;14(8):1320–1325.
   Google Scholar
• Rajupet S, Doshi D, Wisnivesky JP, et al. Attitudes about lung cancer screening: primary care providers versus specialists. Clin Lung Cancer. 2017;18(6): e417–e423.
   PubMed Web of Science ®Google Scholar
• Triplette M, Kross EK, Mann BA, et al. An assessment of primary care and pulmonary provider perspectives on lung cancer screening. AnnalsATS. 2018;15(1):69–75.
   Google Scholar
• Chen T-H-H, Yen AM-F, Fann JC-Y, et al. Clarifying the debate on population-based screening for breast cancer with mammography. A systematic review of randomised controlled trials on mammography with Bayesian met-analysis and causal model. Medicine (Baltimore). 2017;96(3):e5684:1–12.
   Web of Science ®Google Scholar
• Pastorino U, Silva M, Sestini S, et al. Prolonged lung cancer screening reduced 10-year Mortality in the MILD Trial. New confirmation of lung cancer screening efficacy. Ann Oncol. 2019;mdz117. DOI:10.1093/annonc/mdz117/5425325.
   PubMed Web of Science ®Google Scholar
• Mazzone PJ, Sears CR, Arenberg DA, et al. Evaluating molecular biomarkers for the early detection of lung cancer: when is a biomarker ready for clinical use? An Official American thoracic society policy statement. Am J Respir Crit Care Med. 2017;196(7):e15–e29.
   PubMed Web of Science ®Google Scholar
• Atwater T, Massion PP. Biomarkers of risk to develop lung cancer in the new screening era. Ann Transl Med. 2016;4(8):158(1–6).
   PubMed Web of Science ®Google Scholar
• Young RP, Hopkins RJ, Duan F, et al. Genetic risk score from 12SNP panel predicts lung cancer lethality in the National Lung Screening Trial (NLST) – A validation Study in the NLST-ACRIN (N=10,054). Am J Respir Crit Care Med. 2018;197:A2475.
   Web of Science ®Google Scholar
• Young RP, Hopkins RJ, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J. 2007;30:616–622.
   PubMed Web of Science ®Google Scholar
• Lembicz M, Gabryel P, Brajer-Luftmann B, et al. Comorbidity in patients undergoing surgery fro lung cancer. Do we have an adequate tool to assess it? Adv Respir Med. 2017;85:55–63.
   PubMed Web of Science ®Google Scholar
• Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet. 2018;19:581–590.
   PubMed Web of Science ®Google Scholar
• Young RP, Hopkins RJ, Hay BA, et al. Lung cancer susceptibility model based on age, family history and genetic variants. PLoS ONE. 2009;4(4):e5302(1–9).
   Web of Science ®Google Scholar
• Young RP, Hopkins RJ. Identifying patients for whom lung cancer screening is preference-sensitive. Ann Int Med. 2018;169:822–823.
   PubMed Web of Science ®Google Scholar
• Young RP, Hopkins RJ, Duan F, et al. Genetic-based approach to stratifying risk of lung cancer out-performs the PLCOM2012 – optimisation of CT screening outcomes in the NLST-ACRIN sub-study (n=10,054). Am J Respir Crit Care Med. 2018;197:A4422.
   Google Scholar